Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy.

Drugs Context · 2025 · PMC12083858 · PMID 40385566

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

First, the PALOMA-2 trial 14 demonstrated significantly longer PFS in patients with HR + /HER2 − advanced BC treated with palbociclib in combination with standard ET than in those receiving ET, whilst the PALOMA-3 trial 15 showed a longer OS, that did not achieve significance, amongst patients with HR + /HER2 − advanced BC treated with palbociclib-fulvestrant compared to those receiving placebo-fulvestrant.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.